Sunovion Europe announces new name

Sunovion Pharmaceuticals Europe Ltd. (Sunovion Europe) today announces that it has formally changed its name from Dainippon Sumitomo Pharma Europe Ltd. (DSPE). A subsidiary of top ten-listed Japanese pharmaceutical company, Dainippon Sumitomo Pharma Co., Ltd (DSP), Sunovion Europe is headquartered in London. Its main therapeutic focus is in psychiatry and neurology including mental health, in addition to other areas of unmet medical need that require highly specialised early stage clinical development.

Dr Mike Taylor, Managing Director, commented: “This represents a significant landmark in the evolution of our European business, as we prepare to commercialise our first drug in the UK. At Sunovion Europe we focus on the development and introduction of innovative medicines that improve people’s health and well-being. We will continue to focus on psychiatry & neurology and over time will grow the European Business to include other areas.”

Sunovion Europe has the central role in the DSP Group for the development of pharmaceuticals in Europe. It is also preparing to commercialise the DSP Group’s strategic product, the atypical antipsychotic lurasidone hydrochloride (generic name) in the UK. As DSP is now broadening its capabilities in the UK by creating this commercial organisation, it was agreed to change the name to DSP’s international brand “Sunovion”.

Currently, DSP’s partner in Europe for lurasidone hydrochloride, Takeda Pharmaceutical Company Limited, has submitted a Marketing Authorization Application (MAA) for schizophrenia that has been filed by the European Medicines Agency.